Norovirus tablet vaccine shows positive results in Phase 1 study
by Press Release from Outbreak News Today on (#2CREE)
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced Tuesday that its norovirus tablet vaccine met the primary and secondary endpoints for safety and immunogenicity in a Phase 1 clinical trial. "The norovirus Phase 1 results are an important milestone for our oral vaccine ["]
The post Norovirus tablet vaccine shows positive results in Phase 1 study appeared first on Outbreak News Today.